Table 4.

Altered expression of genes proposed previously to be affected by AZM treatment (15, 18, 41)

Locus tag	Name	Fold change due to AZM treatment
		MHB	RPMI	RPMI/serum
PA3477	rhlR	−1.8	−3.6	−8.5
PA3476	rhlI	−1.9	—	−2.3
PA1430	lasR	—	−3.5	−4.3
PA1432	lasI	—	—	−2.0
PA2587	pqsH	—	−2.3	−6.3
PA1003	mvfR (pqsR)	—	2.2	−2.6
PA0996	pqsA	—	1.9	−3.0
PA0997	pqsB	—	—	−4.9
PA0998	pqsC	—	—	−4.8
PA0999	pqsD	—	—	−2.6
PA1000	pqsE	—	—	−2.0
PA2586	gacA	—	—	−1.6
PA2395	pvdO	−3.1	−2.3	—
PA2396	pvdF	—	−3.1	−2.6
PA2397	pvdE	—	−2.5	−3.5
PA2398	fpvA	−3.9	—	—
PA2399	pvdD	—	−2.1	—
PA1148	toxA	—	−2.6	−5.5
PA2663	ppyR	−3.5	−4.1	−2.1
PA1871	lasA	−4.0	−27.0	−45.4
PA3724	lasB	−5.0	−25.1	−27.8
PA2231	pslA	1.9	2.4	—
PA2232	pslB	—	—	−2.7
PA2233	pslC	—	—	−3.2
PA2234	pslD	—	—	−2.5
PA2235	pslE	—	—	−2.7
PA2236	pslF	—	−2.4	−4.8
PA2237	pslG	—	—	−3.4
PA2238	pslH	—	−3.4	−4.8
PA2239	pslI	—	−2.6	−5.0
PA0427	oprM	—	1.9	2.1
PA3297		—	1.7	2.5
PA0585		—	−2.6	−4.2
PA0586		−3.1	−69.0	−59.2
PA0587		−2.7	−47.2	−44.5
PA0588		−2.7	−27.7	−29.4

Values are shown as fold change, obtained from RNA-Seq experiments (with adjusted P ≤ 0.05) for P. aeruginosa PAO1 treated with effective concentrations of AZM vs. untreated samples after growth in MHB, RPMI + 5% MHB (RPMI), and RPMI + 5% MHB + 20% human-serum (RPMI/serum). Samples with a dash signify no change. Not shown are rsmZ, rsmY, pvdN, mexA, or mexB, for which no changes were observed in any medium.